SCHEMBL2405271

SCHEMBL2405271

O=[N+]([O-])c1cc(Cl)cc(-c2cccc(-c3nnn[nH]3)c2)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
DUSP3 P51452 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 1/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404020 0.90 MAPT (0.38) MAPTALDH1A1GAANPSR1CRHBP
SCHEMBL3360994 0.88 GPR35 (0.44) MAPTALDH1A1CRHBPCRHR2MEN1
SCHEMBL2406795 0.75 MEN1 (0.46) MAPTALDH1A1NPSR1MEN1KMT2A
SCHEMBL12310843 0.75 GPR35 (0.51) MAPTALDH1A1GAANPSR1MEN1
SCHEMBL16366189 0.74 F2 (0.32) MAPTALDH1A1CRHBPCRHR2MEN1
SCHEMBL2404465 0.73 ERN1 (0.57) MAPTCRHBPCRHR2DUSP3TTR
SCHEMBL2410713 0.73 CRHBP (0.43) MAPTALDH1A1GAANPSR1CRHBP
SCHEMBL29386074 0.73 ERN1 (0.57) MAPTCRHBPCRHR2DUSP3TTR
SCHEMBL27579533 0.73 FASN (0.37) MAPTALDH1A1CRHBPCRHR2DUSP3
SCHEMBL2406951 0.72 ALDH1A1 (0.49) MAPTALDH1A1GAANPSR1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
US-20090176973-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2009-07-09 US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885
US-20090176973-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885GAA 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.